|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300074392 |
|
最近更新日期: Date of Last Refreshed on: |
2023-08-04 17:08:36 |
|
注册时间: Date of Registration: |
2023-08-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于多模态数据建立预测高血压患者的危险分层评分体系的研究 |
|
Public title: |
Establishment of a risk stratification scoring system for predicting hypertensive patients based on multimodal data |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于多模态数据建立预测高血压患者的危险分层评分体系的研究 |
|
Scientific title: |
Establishment of a risk stratification scoring system for predicting hypertensive patients based on multimodal data |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王钧 |
研究负责人: |
唐龙 |
|
Applicant: |
Jun Wang |
Study leader: |
Long Tang |
|
申请注册联系人电话: Applicant telephone: |
+86 178 5613 0299 |
研究负责人电话:
Study leader's |
+86 189 5630 0320 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
junwang0607@163.com |
研究负责人电子邮件: Study leader's E-mail: |
812595591@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
安徽省蚌埠市龙子湖区蚌埠医学院第一附属医院 |
研究负责人通讯地址: |
安徽省宣城市宣州区宣城市人民医院内科楼6楼心血管内二科医生办公室 |
|
Applicant address: |
The First Affiliated Hospital of Bengbu Medical College,Longzihu District,Bebgbu City,Anhui Province |
Study leader's address: |
15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
安徽省蚌埠市龙子湖区蚌埠医学院第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Bengbu Medical College,Longzihu District,Bebgbu City,Anhui Province |
||
|
研究负责人所在单位: |
安徽省宣城市宣州区宣城市人民医院内科楼6楼心血管内二科医生办公室 |
||
|
Affiliation of the Leader: |
15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-1w008-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
宣城市人民医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee of Xuancheng People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-30 00:00:00 | ||
|
伦理委员会联系人: |
张年宝 |
||
|
Contact Name of the ethic committee: |
Nianbao Zhang |
||
|
伦理委员会联系地址: |
安徽省宣城市宣州区宣城市人民医院 |
||
|
Contact Address of the ethic committee: |
15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 181 5633 5568 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
宣城市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The People's Hospital of Xuancheng City |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
安徽省宣城市宣州区环城北路15号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
15 Huancheng Road North, Xuanzhou District, Xuancheng, Anhui, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-financing |
||||||||||||||||||||||
|
研究疾病: |
高血压 |
||||||||||||||||||||||
|
Target disease: |
Hypertension |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
探讨高血压患者预后的影响因素,并基于多模态数据构建预测模型 模型,以便于早期识别主要不良心脑血管事件( Main Adverse Cardiovascular and Cerebrovascular Events, MACCEs ) 高风险的预测价值 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the factors influencing the prognosis of hypertensive patients and to construct a predictive model based on multimodal data Models for early identification of Main Adverse Cardiovascular and Cerebrovascular Events ( Main Adverse Cardiovascular and Cerebrovascular Events, MACCEs ) Predictive value of high-risk |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 年龄为18-95岁之间; 2. 入院时诊断为高血压; |
||||||||||||||||||||||
|
Inclusion criteria |
1. age between 18 and 95 years; 2. a diagnosis of hypertension at the time of admission; |
||||||||||||||||||||||
|
排除标准: |
1. 继发性高血压; 2. 既往行冠状动脉搭桥手术; 3. 合并严重的心脏瓣膜疾病; 4. 活跃的心肌炎; 5.活跃的心包炎; 6. 有严重感染; 7. 严重肾功能不全(eGFR<30ml/min) 8. 风湿免疫系统疾病; 9. 精神上或法律上的丧失行为能力; 10.过去2年内滥用药物或酒精; 11. 基础心律非窦性节律患者(如心房扑动、心房颤动、严重房室传导阻滞及起搏器植入等; 12. 有肿瘤相关疾病; 13. 存在对自主神经功能有影响的其他疾病,如甲状腺功能亢进症、精神系统或者神经系统疾病等; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. secondary hypertension; 2. prior coronary artery bypass graft surgery. 3. comorbid severe heart valve disease; 4. active myocarditis 5. active pericarditis 6. severe infections; 7. severe renal insufficiency (eg. 7. severe renal insufficiency (eGFR < 30 ml/min) 8. rheumatologic diseases; 9. mental or legal incapacity. 10. drug or alcohol abuse within the last 2 years. 11. patients with an underlying rhythm other than sinus rhythm (e.g., atrial flutter, atrial fibrillation, severe atrioventricular block, and pacemaker implantation; 12. the presence of tumor-related diseases 13. the presence of other diseases that have an impact on autonomic function, such as hyperthyroidism, psychiatric or neurological disorders. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-08-06 00:00:00至 To 2023-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-08-06 00:00:00 至 To 2023-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据由病例记录表和电子采集系统采集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data is captured and managed by case record forms and electronic capture systems |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |